Crizotinib (PF-02341066)

Pfizer辉瑞授权目录号：S1068

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 1812.55	现货
5mg	RMB 900.49	现货
10mg	RMB 1372.81	现货
50mg	RMB 4681.47	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献226篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Cancer Cell, 2011, 19(5):679-90

PubMed: 21575866 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3991

PubMed: 31488816 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )
Clin Cancer Res, 2019, clincanres.1486.2019

PubMed: 31636099 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1667

PubMed: 31548343 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):139

PubMed: 30760701 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31334113 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480591 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )
BMC Cancer, 2019, 19(1):1044

PubMed: 31690270 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):1231-1240

PubMed: 30653748 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4086-4097

PubMed: 29990309 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(12):2732-2739

PubMed: 29559559 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )
Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Front Oncol, 2018, 8:460

PubMed: 30464927 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5983-5991

PubMed: 30333869 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3502-3512

PubMed: 28512244 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3013

PubMed: 28837150 ( click the link to review the publication )

Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )
Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Medchemcomm, 2017, 8(10):1914-1918

PubMed: 30108712 ( click the link to review the publication )

Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Cardiooncology, 2017, 10.1186/s40959-017-0020-z

PubMed: 28217366 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Blood, 2016, 128(9):1234-45

PubMed: 27297792 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(7):1787-99

PubMed: 26667487 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(22):5527-5538

PubMed: 27780853 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6031-6038

PubMed: 27091406 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1506-16

PubMed: 26719536 ( click the link to review the publication )

Cancer Res, 2016, 76(13):3895-903

PubMed: 27197184 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )
Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Endocrine, 2016, 53(1):145-56

PubMed: 26370117 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

PLoS One, 2016, 11(11):e0165983

PubMed: 27832137 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75968-75980

PubMed: 27732954 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Blood, 2015, 126(26):2821-31

PubMed: 26531163 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2916-27

PubMed: 26018086 ( click the link to review the publication )
Oncoimmunology, 2015, 5(3):e1108514

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11-:2433-40

PubMed: 26351321 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0132330

PubMed: 26147305 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0121378

PubMed: 25874976 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124283

PubMed: 25919140 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Oncotarget, 2015, 6(27):24320-32

PubMed: 26172300 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2015, 18(6):330-9

PubMed: 26104888 ( click the link to review the publication )

Oncotarget, 2015, 6(14):11820-32

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )

Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )

Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )
Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Sci Rep, 2013, 3:3450

PubMed: 24356251 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

Molecules, 2013, 18(12):15412-21

PubMed: 24335618 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )

Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )
Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述

靶点

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞，作用于c-Met磷酸化作用时具有相似效果，IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞，具有相似的活性，且活力增高，IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时，IC50为13 nM。^[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时，与作用于野生型受体相比，效果发生显著改变，IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞，也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比，PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍，作用于IRK和Lck选择性高250多倍，作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反，PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值，为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型，和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长，IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡，IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵，IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射，IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活，和Matrigel入侵，IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。^[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞，也有效抑制 NPM-ALK磷酸化，IC50 为24 nM。PF-2341066 有效抑制细胞增殖，伴随着使细胞周期停在G(1)-S期，且诱导 ALK阳性的 ALCL 细胞凋亡，IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 ^[2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长 (例如,增殖和存活)和转移 (例如，入侵和形成克隆)。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BAF3	NEHLNplEgXSxdH;4bYMhSXO\|YYm=		NFHMSXY1QCCq	NEPaRmdFVVOR	M4KyeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2=	NWPhOJlPOjF3N{K1PFk>
BAF3	MUHDfZRwfG:6aXOgRZN{[Xl?		M4jWW\|Q5KGh?	M{L6S2ROW09?	NVvjNJJ5S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BNOTF7Nl2gcZV1[W62IHPv[ZhxemW\|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAzNjJizszN	NUO4NG5oOjF3N{K1PFk>
BAF3	MYTDfZRwfG:6aXOgRZN{[Xl?		MX:0PEBp	MWnEUXNQ	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR\|UxKG:oIECuNlgh\|ryP	M1PCbVIyPTd{NUi5
Kelly	NXXxR3lnS3m2b4TvfIlkKEG\|c3H5			Ml3TSG1UVw>?	MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KHerdHigTWM2OCCxZjCwMlQzKM7:TR?=	NX3YXpZ6OjF3N{K1PFk>
SH-SY5Y	MYPDfZRwfG:6aXOgRZN{[Xl?			Ml:xSG1UVw>?	MoHWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjV\|IN88US=>	NEjS[mkzOTV5MkW4PS=>
SMS-KCN	MlvXR5l1d3SxeHnjJGF{e2G7			MlTmSG1UVw>?	MlW2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV21UNUuFTjDj[YxteyCneIDy[ZN{cW6pIFHMT{BTOTJ5NWGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjlzIN88US=>	NYjZcFF6OjF3N{K1PFk>
BAF3	M1;jUWN6fG:2b4jpZ{BCe3OjeR?=		MkLvOFghcA>?	NHL6XI9FVVOR	MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXGWuLVHMT{B4cXSqIFnDOVAhd2ZiMD6xPUDPxE1?	M1q1UlIyPTd{NUi5
3T3	M1fVRWZ2dmO2aX;uJGF{e2G7		MkXvNUBp	NVPGT5Y3TE2VTx?=	Mni4TY5pcWKrdHnvckBw\iCUT16gZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEig{txO	MUiyNVgyOjRzNB?=
3T3-E	M{jTPWZ2dmO2aX;uJGF{e2G7		M4ntfVEhcA>?	NVjvXHZrTE2VTx?=	NFLoc2ZKdmirYnn0bY9vKG:oIGTJSVIh[XO\|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>?	NXf0RZFjOjF6MUK0NVQ>
A549	NYHwUIE{U2mwYYPlJGF{e2G7		NXLLPXhHOSCq	NHPTeI9FVVOR	Mn;hTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN	MoO4NlE5OTJ2MUS=
BAF3-BCL	MV\GeY5kfGmxbjDBd5NigQ>?		M3\wPVEhcA>?	MYXEUXNQ	M2fKbWlvcGmkaYTpc44hd2ZiQVLMJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1?	MnPkNlE5OTJ2MUS=
HEK293	NF3nUpVHfW6ldHnvckBCe3OjeR?=		NYfCdppQOSCq	NWH6TG1ZTE2VTx?=	MX3Jcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO	MnjHNlE5OTJ2MUS=
HEK293	M1i2OmZ2dmO2aX;uJGF{e2G7		NWrlO2JyOSCq	MorvSG1UVw>?	MXHJcohq[mm2aX;uJI9nKEmUIHHzd4V{e2WmIHHzJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAzNjh6NzFOwG0>	Mn24NlE5OTJ2MUS=
Jurkat	Mn\NSpVv[3Srb36gRZN{[Xl?		M1OyTVEhcA>?	NWTZN\|Q2TE2VTx?=	M1fJVmlvcGmkaYTpc44hd2ZiTFPLJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lke0NUDPxE1?	MnnjNlE5OTJ2MUS=
KARPAS299	M{XkUWtqdmG\|ZTDBd5NigQ>?		MWSxJIg>	MWnEUXNQ	MkH6TY5pcWKrdHnvckBw\iCDTFugZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO	Ml71NlE5OTJ2MUS=
PAE	MVPGeY5kfGmxbjDBd5NigQ>?		M1q1b\|EhcA>?	M1zBeWROW09?	M1nkcWlvcGmkaYTpc44hd2ZiVGLLRkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6zPVkh\|ryP	MWmyNVgyOjRzNB?=
BAF3	MVnGeY5kfGmxbjDBd5NigQ>?		MU[yMVMh\A>?	MUnEUXNQ	MlTxTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiaX7zeYxqdiC{ZXPldJRweiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvPjR\|IN88US=>	M3TWN\|I{PzR{MkWy
KARPAS299	M2O4fGN6fG:2b4jpZ{BCe3OjeR?=		NEe5dnozNTNiZB?=	MV7EUXNQ	NELyfXJKSzVyPUCuNFY1OiEQvF2=	NHjEdHozOzd2MkK1Ni=>
EBC1	MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnLxO\|IhcA>?	NW\aPZNHTE2VTx?=	NI\YV3pKSzVyPUCuNFI{KM7:TR?=	M3vBfVI{QTl\|M{K4
HCT116	M3Xqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3n4WlczKGh?	NUDodXB7TE2VTx?=	NHvjWpdKSzVyPUG0MlgzKM7:TR?=	M3nsT\|I{QTl\|M{K4
MCF7	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4PNXlczKGh?	MVXEUXNQ	MXvJR\|UxRTlwNUig{txO	NVrNRYNpOjN7OUOzNlg>
MDA-MB-231	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFfrN4M4OiCq	NXriUnJHTE2VTx?=	MkHnTWM2OD1zMD64JO69VQ>?	MWCyN\|k6OzN{OB?=
MKN45	M1nofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYW3NkBp	NGCzdZhFVVOR	NYT0SYxuUUN3ME2wMlAyOyEQvF2=	MYSyN\|k6OzN{OB?=
NCI-H441	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXnaPFlPPzJiaB?=	NEDPVWdFVVOR	Mo\0TWM2OD1zNz6yOUDPxE1?	MX[yN\|k6OzN{OB?=
NCI-H661	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnHIO\|IhcA>?	NUHEeod2TE2VTx?=	MljQTWM2OD1zMT60O{DPxE1?	MXiyN\|k6OzN{OB?=
SK-MEL-28	NX7qXZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmXaO\|IhcA>?	NIDmWHJFVVOR	MVPJR\|UxRTFyLkm3JO69VQ>?	NYLHNo5JOjN7OUOzNlg>
SKOV3	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYLJ[mN4PzJiaB?=	M2i4W2ROW09?	NWS2TJV7UUN3ME2xNk45PSEQvF2=	NVnwe\|AxOjN7OUOzNlg>
SNU5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NW\zNmJwPzJiaB?=	MYHEUXNQ	MljMTWM2OD1yLkCxOkDPxE1?	NUfXTpBNOjN7OUOzNlg>
NCI-H2228	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEL4VZQ4OiCq	NGG4PXhFVVOR	M2PUe2lvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFzODFOwG0>	MV6yOFQ{OjlyOR?=
NCI-H3122	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFfUZ484OiCq	NWjY[YNMTE2VTx?=	NVvaXZFHUW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUC4JO69VQ>?	NELQb4kzPDR\|MkmwPS=>
NCI-H3122	M2W2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGLvd3k4OiCq	MYnEUXNQ	NIjPbYVKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0>	NWjzbVJMOjR2M{K5NFk>
NCI-H3122	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWHYcG1kPzJiaB?=	MXTEUXNQ	M2HpfGlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGwyOTl4TTDteZRidnRid3n0bEBKSzVyIH;mJFAvQDN6IN88US=>	NV6wbYFyOjR2M{K5NFk>
NIH-3T3	Ml\CT4lv[XOnIFHzd4F6		Mom4NUBp	MkjmSG1UVw>?	M1jNcGlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTl[EBCVEtibHX2[Ywhf2m2aDDJR\|UxKG:oIECuNFgh\|ryP	M2P6clI1PDN{OUC5
NIH-3T3	Mli0T4lv[XOnIFHzd4F6		MYexJIg>	NIDrO\|NFVVOR	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlY6SSCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZyNTFOwG0>	MWGyOFQ{OjlyOR?=
NIH-3T3	MYnLbY5ie2ViQYPzZZk>		MY[xJIg>	M3X5UmROW09?	NULlNXB5UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:\|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh\|ryP	MXqyOFQ{OjlyOR?=
NIH-3T3	M3yzZmtqdmG\|ZTDBd5NigQ>?		NInDbXoyKGh?	M17jTWROW09?	Mn7iTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC56NEOg{txO	NGf6VoIzPDR\|MkmwPS=>
NIH-3T3	NIm2T\|dMcW6jc3WgRZN{[Xl?		MYqxJIg>	MUPEUXNQ	NWLMT4ZwUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:\|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh\|ryP	MVWyOFQ{OjlyOR?=
BAF3	MV\GeY5kfGmxbjDBd5NigQ>?		NInjSJc4OiCq	NVL2[Hc3TE2VTx?=	NGL5fVVKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO	NYDyOVM2OjR2Nki2N\|I>
BAF3	M1T1VWN6fG:2b4jpZ{BCe3OjeR?=		MnT6O\|IhcA>?	M13ZWGROW09?	Mn7STWM2OD1yLkm4JO69VQ>?	MmPVNlQ1Pjh4M{K=
NIH-3T3	MWDLbY5ie2ViQYPzZZk>		NVP3cYNkOSCq		NETyPXNKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkG2OUDPxE1?	NV3CVIdXOjR6MUmxNVY>
NIH-3T3	NIDDellMcW6jc3WgRZN{[Xl?		MXGxJIg>		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0>	NYHPdI5KOjR6MUmxNVY>
NIH-3T3	NIDvUHBMcW6jc3WgRZN{[Xl?		MoXXNUBp		MXvJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0>	NIPM[mszPDhzOUGxOi=>
NIH-3T3	MUfLbY5ie2ViQYPzZZk>		M4fDZVEhcA>?		NV25[ItTUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2=	M4TERVI1QDF7MUG2
KARPAS299	NEHGN5hMcW6jc3WgRZN{[Xl?		NI\YW2I6OCCvaX6=	MUTEUXNQ	M{nEWGlvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:\|cHjvdplt[XSrb36g[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>?	M1K1[\|I1QTByN{Ww
MKN 45	NHXmZm1McW6jc3WgRZN{[Xl?		MlHZNUBp	NIrhZolFVVOR	MkThTY5pcWKrdHnvckBw\iClLV3leEBxcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO	NH7lZlgzPDlyMEe1NC=>
A549	MXrDfZRwfG:6aXOgRZN{[Xl?		NFe0ZpQ1QCCq	M{jWOWROW09?	Ml7XTWM2OCCxZjC0MlA5PCEQvF2=	M2HZfFI1QTByOEOw
NCI-H1975	MUfDfZRwfG:6aXOgRZN{[Xl?		NIjSTGk1QCCq	MV;EUXNQ	Ml\UTWM2OCCxZjC3MlU2OSEQvF2=	Ml71NlQ6ODB6M{C=
NCI-H1993	NGntb\|hEgXSxdH;4bYMhSXO\|YYm=		Mn\MOFghcA>?	NUTQWWVoTE2VTx?=	MmjmTWM2OCCxZjCwMlA3OSEQvF2=	M3iyc\|I1QTByOEOw
NCI-H1993	NVPGNJE5SXCxdH;zbZMhSXO\|YYm=	Mk\KNUDPxE1?	NIPH[2YzPCCq	M1HSXGROW09?	NF3hTZlld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	M335OVI1QTByOEOw
NIH-3T3	M1\hPGN6fG:2b4jpZ{BCe3OjeR?=		MnXtOFghcA>?	NWXxOHpXTE2VTx?=	M1HUUmlEPTBib3[gNE4{PjRizszN	M4rCNVI1QTByOEOw
EBC1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkiwO\|IhcA>?	M3rNcmROW09?	NHrPdYRKSzVyIH;mJFAvODB4OTFOwG0>	M1XyOlI1QTByOEOx
KARPAS299	NF65Tm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml3EO\|IhcA>?	MoP5SG1UVw>?	MU\JR\|UxKG:oIECuNkDPxE1?	MUeyOFkxODh\|MR?=
NB1	NYLOOo5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTlzLkm4JI5O	NFe1TYxUSU6JRWK=
NCI-SNU-5	Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mof5TWM2OD1zMEWuO\|Uhdk1?	NXLMNG5ZW0GQR1XS
SR	NVHYOFNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvkUFVYUUN3ME2xNlYvOzFibl2=	M3LUUnNCVkeHUh?=
SF539	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrHUHpKSzVyPUKwOE4zPCCwTR?=	M2HS[nNCVkeHUh?=
SU-DHL-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTN\|Nj64NkBvVQ>?	MmLqV2FPT0WU
SCC-3	NID5NIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTN3Nj63OkBvVQ>?	NIPLemVUSU6JRWK=
DEL	NWnucmhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DwWWlEPTB;M{[5Mlkhdk1?	NXrZTJNxW0GQR1XS
CTV-1	M4\lfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTV7Nj60PEBvVQ>?	MkjLV2FPT0WU
EM-2	M1P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIS5OnFKSzVyPU[wNU4{PCCwTR?=	NES3[IZUSU6JRWK=
MHH-CALL-2	NGfZUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTZ6Mj61O{BvVQ>?	MW\TRW5ITVJ?
KM12	NWjCeoJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\oUmlEPTB;N{C2Mlkhdk1?	MkTGV2FPT0WU
KINGS-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;JeFNKSzVyPUe0PU44PSCwTR?=	Mme4V2FPT0WU
MEG-01	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Pv[WlEPTB;OEW3MlY3KG6P	NYPxeIF7W0GQR1XS
BV-173	MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITUR3JKSzVyPUGuNFU6QTdizszN	M{T1V3NCVkeHUh?=
LAMA-84	M2HYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUGxSWJNUUN3ME2xMlM5Ojh{IN88US=>	MoXvV2FPT0WU
KARPAS-299	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDtTWM2OD1zLkSwPFYyKM7:TR?=	M{i0[3NCVkeHUh?=
K-562	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlr3TWM2OD1zLkeyNlY6KM7:TR?=	M1rUbXNCVkeHUh?=
SK-LMS-1	NGDEWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfuTWM2OD1zLke2PFY4KM7:TR?=	MoHWV2FPT0WU
MOLT-16	M16xSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\nXW5lUUN3ME2xMlk2PTd3IN88US=>	M{fzXHNCVkeHUh?=
CMK	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTFwOU[xOVkh\|ryP	M4D1XXNCVkeHUh?=
ST486	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjxVHdvUUN3ME2yMlQ{ODd\|IN88US=>	NUjnVo56W0GQR1XS
CI-1	NIKzVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn3[JhKSzVyPUKuOFk3PTlizszN	MXnTRW5ITVJ?
KP-N-RT-BM-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rMWmlEPTB;Mj63NFEzOiEQvF2=	MXfTRW5ITVJ?
ALL-PO	M{LIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXQXoNYUUN3ME2zMlE5OjB5IN88US=>	NH7V[VNUSU6JRWK=
KS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTNwMkGyNlUh\|ryP	NGfzfWFUSU6JRWK=
Becker	MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTRwMkO5N{DPxE1?	NXLNTFZsW0GQR1XS
GDM-1	M2HSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTRwMkS2NVch\|ryP	Ml:wV2FPT0WU
BC-1	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TpNmlEPTB;ND60PVI4PyEQvF2=	NGr0OZVUSU6JRWK=
NB14	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHNTWM2OD12LkizOVI1KM7:TR?=	NIrsd4VUSU6JRWK=
NOS-1	NIjzZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL5bXVKSzVyPUWuN\|M5PzRizszN	NUn1WYdQW0GQR1XS
MZ1-PC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PCV2lEPTB;NT64NlE2OSEQvF2=	NWTaWohvW0GQR1XS
A498	NWTLd3EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;SWGlEPTB;Nj6wPFQ4OyEQvF2=	MlHrV2FPT0WU
EW-16	NGL2TXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Tic2lEPTB;Nj6zO\|c4OyEQvF2=	M2LEeXNCVkeHUh?=
NALM-6	NH3IUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fkT2lEPTB;Nj62PFM5PyEQvF2=	M1rabHNCVkeHUh?=
EB-3	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTdwMEeyN\|Mh\|ryP	M1jR[nNCVkeHUh?=
697	NFvIXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvmcpVKSzVyPUmuNlQ{OjlizszN	NWLiSlh{W0GQR1XS
Ramos-2G6-4C10	M{C5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXtTWM2OD17LkW5PFQzKM7:TR?=	NXHudZZ6W0GQR1XS
KNS-81-FD	NESzeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTlwNkm2OVMh\|ryP	NH\qTI1USU6JRWK=
HUTU-80	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXlc\|VKSzVyPUmuO\|Q3PDJizszN	NF\Kc3VUSU6JRWK=
LS-411N	NVvSRlBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV31Zmc5UUN3ME2xNE4xPTZ5IN88US=>	M1nVTXNCVkeHUh?=
RPMI-8402	Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf2Oo5QUUN3ME2xNE4yOTZizszN	MXHTRW5ITVJ?
KU812	M2n1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFyLkK5PVEh\|ryP	M4r1S3NCVkeHUh?=
EW-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrwXVdKSzVyPUGwMlQ1OjVizszN	MoXxV2FPT0WU
HC-1	M3fmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTFyLkS4OFQh\|ryP	MVPTRW5ITVJ?
NB69	M3vLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFyLkWwOFMh\|ryP	MlzhV2FPT0WU
MFH-ino	NF[2VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFyLkizNFMh\|ryP	MorlV2FPT0WU
CCRF-CEM	NGHFc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPacFBFUUN3ME2xNU42QTdizszN	NHWyfo1USU6JRWK=
SK-N-DZ	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWK2TZlLUUN3ME2xNk4xPDN4IN88US=>	MlzkV2FPT0WU
NCI-H720	NH;nW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\Ld4hKSzVyPUGyMlE4ODVizszN	M1\DS3NCVkeHUh?=
HCC1187	NYW4d\|FvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTF{LkKwOFEh\|ryP	NXPnc5pnW0GQR1XS
IST-SL2	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1robGlEPTB;MUKuOFg4OiEQvF2=	MVPTRW5ITVJ?
KE-37	NFXqZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF{Lke5OlYh\|ryP	NIXaOolUSU6JRWK=
HCC1599	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2GyXWlEPTB;MUKuPVA3QSEQvF2=	NIjiOpRUSU6JRWK=
A4-Fuk	MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTF{Lkm1PFYh\|ryP	Mke1V2FPT0WU
NKM-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTF\|LkK5NlUh\|ryP	NEi3[G5USU6JRWK=
BE-13	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fiZWlEPTB;MUOuO\|k5QSEQvF2=	Ml3pV2FPT0WU
MV-4-11	M2rxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTF2LkCzNlQh\|ryP	MnLjV2FPT0WU
OPM-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;Rd2lEPTB;MUSuOFA5PSEQvF2=	NF3nV4NUSU6JRWK=
KARPAS-422	NUjq[2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTF2LkWxNlYh\|ryP	M4P0enNCVkeHUh?=
RPMI-8226	NV;zb2pNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEj0fWtKSzVyPUG0Mlg6OTVizszN	M1HienNCVkeHUh?=
KARPAS-45	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPkTWM2OD1zNT63O\|E3KM7:TR?=	M1flV3NCVkeHUh?=
SK-PN-DW	NFLm[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvpc3ZmUUN3ME2xOU45PjNzIN88US=>	NX;wc\|B[W0GQR1XS
LC-2	M4LiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTF4LkG1NFYh\|ryP	MYTTRW5ITVJ?
NCI-H1648	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojVTWM2OD1zNj6yOVQh\|ryP	MWTTRW5ITVJ?
RL95-2	NFjhWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTF4LkO5O\|gh\|ryP	NX3GdlN[W0GQR1XS
KNS-42	M4XkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DYVGlEPTB;MU[uO\|I4PCEQvF2=	NWfrOGN2W0GQR1XS
RPMI-6666	NUDXZlNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XTZ2lEPTB;MU[uPVIyOSEQvF2=	MY\TRW5ITVJ?
SIG-M5	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonlTWM2OD1zNz6xPVA{KM7:TR?=	Mn:3V2FPT0WU
VA-ES-BJ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPPVJhKSzVyPUG3Mlc1PTFizszN	MnTUV2FPT0WU
MONO-MAC-6	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fLemlEPTB;MUeuPVMyOiEQvF2=	M3zkRnNCVkeHUh?=
LAN-6	M37VXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvMOnJKSzVyPUG4Mlc2PTdizszN	MYTTRW5ITVJ?
A388	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGe5TYRKSzVyPUG5MlMxPTlizszN	M3rmWXNCVkeHUh?=
SK-NEP-1	NVW5fpppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHNTWM2OD1{MD6yNVMzKM7:TR?=	NHTaN5BUSU6JRWK=
TE-10	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y0Z2lEPTB;MkCuOVIzOSEQvF2=	MUXTRW5ITVJ?
HL-60	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnR[YRKSzVyPUKwMlkxQTlizszN	Mn\hV2FPT0WU
MC116	Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmm0TWM2OD1{MT63NlIyKM7:TR?=	NHG4RpVUSU6JRWK=
SW962	MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\iSmlEPTB;MkGuO\|kyPSEQvF2=	MYXTRW5ITVJ?
NOMO-1	MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1uyRmlEPTB;MkKuOlU3PCEQvF2=	MlTnV2FPT0WU
CTB-1	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PNZmlEPTB;MkKuPFY4OSEQvF2=	NIDZb2hUSU6JRWK=
MRK-nu-1	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\1T2FKSzVyPUKyMlkxPzRizszN	NYDXd2N{W0GQR1XS
GR-ST	NITkbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTJ\|Lke2JO69VQ>?	MmO5V2FPT0WU
HH	MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LNbmlEPTB;MkSuNFA{KM7:TR?=	MnTTV2FPT0WU
NCI-H1963	NGe2[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFruSoNKSzVyPUK0MlA4QDJizszN	NFnkeFBUSU6JRWK=
QIMR-WIL	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3BRVRKSzVyPUK0Mlg4PzJizszN	MVnTRW5ITVJ?
CGTH-W-1	NYHEbWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTJ3LkC3NlMh\|ryP	Mn7BV2FPT0WU
LP-1	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LkRmlEPTB;MkWuOlU2OSEQvF2=	Mn62V2FPT0WU
NCI-H748	M2LD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TuZmlEPTB;Mk[uOVE{PyEQvF2=	NXnJUWpNW0GQR1XS
PF-382	NVPCOok6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnHWFF1UUN3ME2yO{4zOjJ\|IN88US=>	NECxd29USU6JRWK=
ATN-1	NFzsPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1qxbGlEPTB;MkeuN\|c{OiEQvF2=	M{PTdXNCVkeHUh?=
L-540	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXnT5lKSzVyPUK3MlY1PTlizszN	MXvTRW5ITVJ?
LXF-289	NFfIN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjqNFRGUUN3ME2yO{44PTF7IN88US=>	NVHqWYNnW0GQR1XS
LS-513	NHLQZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLnTWM2OD1{OD6xPFA4KM7:TR?=	MXvTRW5ITVJ?
NCI-H1581	M2fydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jSU2lEPTB;M{CuN\|k4PiEQvF2=	MVPTRW5ITVJ?
ES6	NWCwW3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTNyLk[4PVkh\|ryP	NV7abotGW0GQR1XS
SW982	NIPUboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFP6SnhKSzVyPUOwMlg2PjZizszN	NYXyNJM4W0GQR1XS
DOHH-2	NYXwW\|Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;S[ItKSzVyPUOxMlU5QTNizszN	NV\rWlFYW0GQR1XS
DB	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzFfmtQUUN3ME2zN{46PDNzIN88US=>	NV3ueZpMW0GQR1XS
MPP-89	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPyRWY3UUN3ME2zOE4yPzV4IN88US=>	MWfTRW5ITVJ?
LB831-BLC	M1vEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2P3eGlEPTB;M{SuOVE5PCEQvF2=	MXjTRW5ITVJ?
NB5	NIe0XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX62PGZRUUN3ME2zOE45PTN3IN88US=>	MXTTRW5ITVJ?
GB-1	M1P2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTN3LkC0Olkh\|ryP	NYHtenUzW0GQR1XS
TE-15	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTN3LkKyN\|gh\|ryP	MY\TRW5ITVJ?
LC4-1	NVPQO3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDJOHNqUUN3ME2zOU4{QDR5IN88US=>	MV7TRW5ITVJ?
NCI-H747	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4OxNGlEPTB;M{[uNVM3QSEQvF2=	M4TrSHNCVkeHUh?=
NTERA-S-cl-D1	NFSwWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTtcXQ1UUN3ME2zPE44OzR5IN88US=>	NVzVW2VxW0GQR1XS
SK-MM-2	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXS4dlNtUUN3ME20NE4yOTR4IN88US=>	MV;TRW5ITVJ?
TGW	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n4NWlEPTB;NEGuNFU3OyEQvF2=	MXjTRW5ITVJ?
ONS-76	NF;EdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjtc2JKSzVyPUSyMlQ5QDNizszN	MnfHV2FPT0WU
CPC-N	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHjNYFLUUN3ME20Nk46QTdzIN88US=>	M{H0R3NCVkeHUh?=
ES4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXX5[XF5UUN3ME20OE41OTV\|IN88US=>	MXTTRW5ITVJ?
Daudi	NYG0dJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkiyTWM2OD12NT6wPFI4KM7:TR?=	NFzJOnZUSU6JRWK=
MOLT-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TO[GlEPTB;NEWuNFg2OyEQvF2=	M3zS[HNCVkeHUh?=
HT-144	NV7pR\|AzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWX0eJNOUUN3ME20Ok44OjZizszN	MoXOV2FPT0WU
SW872	NGrwc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUf4VW44UUN3ME20PE4yQTN\|IN88US=>	M1LqNnNCVkeHUh?=
D-283MED	M2DKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTR6LkO1OFIh\|ryP	Mk\JV2FPT0WU
NCI-H2126	NFX3eGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnJTWM2OD12OD64OFc3KM7:TR?=	MlPzV2FPT0WU
NCI-SNU-16	NFvVXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljtTWM2OD12OT6yNVQ{KM7:TR?=	NVnmVW9nW0GQR1XS
CESS	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LLfGlEPTB;NEmuOVA5QCEQvF2=	MV3TRW5ITVJ?
A101D	Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;WPY03UUN3ME20PU46PzN4IN88US=>	NF:0NnVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm³) 明显衰退，且按43天处理日程处理后，平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上，完全抑制GTL-16肿瘤生长，PF-2341066每天按50 mg/kg剂量处理小鼠，3个月后，只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天，观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型，处理周期为33天，观察到平均肿瘤体积降低53%，且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长，在实验最后一天，抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型，不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤，观察到CD31阳性内皮细胞显著降低，这种作用存在剂量依赖性，说明 MVD 受抑制，且具有相关的抗癌高效性，这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型，显著降低人VEGFA 和IL-8血浆水平，这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤，观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。^[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠，具有抗癌高效性，这种作用存在剂量依赖性，处理15天，所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器，及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂，这些与 NPM-ALK 磷酸化和功能受抑制相关。^[2] PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长(例如, 增殖和存活)和转移 (例如，入侵和形成克隆)。PF-2341066口服饲喂裸鼠，抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。^[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤，引起肿瘤衰退，这与¹⁸F-FDG 摄取的缓慢降低相关，且降低葡糖糖转运蛋白 1, GLUT-1的表达。^[4]

激酶实验： ^[1]	- 合并生化激酶实验: 使用连续耦合的分光光度测定c-Met催化活性，通过分析NADH消耗率而测定c-Met诱导的ADP产量，这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定K_i值, 在含实验试剂的实验孔中加入不同浓度PF-2341066，然后在37^oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验： ^[1]	- 合并 Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞 Concentrations: 0 nM-256 nM Incubation Time: 1小时 Method: GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上，孔中含培养基，培养基中含10% 胎牛血清(FBS)，然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)]，处理 24小时。在调查配体依赖的RTK 磷酸化实验中，加入相应的生长因子，处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时，然后使用含 1 mmol/L Na₃VO₄的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化，使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时，在4^oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸（PY-20）抗体（1:500）中温育20分钟;(d) 再次冲洗7次;(e)在3,3^′,5,5^′-四甲基联苯胺过氧化物酶底物中温育，开始显示反应，加入0.09 N H₂SO₄终止反应; (f)在450 nm 处使用分光光度计测定吸光度。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠 Formulation: -- Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+dd H2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Crizotinib (PF-02341066) SDF

分子量	450.34
化学式	C₂₁H₂₂Cl₂FN₅O
CAS号	877399-52-5
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03439215	Recruiting	Drug: Lorlatinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical Research Technology S.r.l.	June 13 2017	Phase 2
NCT02946216	Unknown status	Genetic: ctDNA analysis	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	Drug: Crizotinib\|Drug: Pembrolizumab	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Recruiting	Drug: crizotinib	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2
NCT02499614	Unknown status	Drug: Crizotinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale	December 2014	Phase 2
NCT02510001	Active not recruiting	Drug: PF-02341066\|Drug: PD-0325901\|Drug: Binimetinib	Solid Tumor\|Colorectal Cancer	University of Oxford\|Queen''s University Belfast\|Oxford University Hospitals NHS Trust\|Velindre NHS Trust\|University Hospital Antwerp\|Hospital Vall d''Hebron\|Saint Antoine University Hospital\|European Georges Pompidou Hospital\|Pfizer\|University of Turin Italy\|Belfast Health and Social Care Trust\|Beaumont Hospital\|European Commission\|Array BioPharma\|University of Paris 5 - Rene Descartes	November 2014	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
回答：
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

选择性强的c-Met抑制剂

PF-04217903 : C-Met-selective, IC50=4.8 nM.
活性最高的c-Met抑制剂

INCB28060 : C-Met, IC50=0.13 nM.
用于临床的c-Met抑制剂

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.
最新的c-Met抑制剂

EMD 1214063 ^New : Potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

研究领域

产品类型

Crizotinib (PF-02341066)

客户使用Selleck该产品发表文献226篇：

产品安全说明书

c-Met抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Crizotinib (PF-02341066) SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品